Please enable JavaScript to continue using this application.

Compare $CTOR vs $HRTX | Chartloom

Compare

$CTOR vs $HRTX

Citius Oncology Inc · Heron Therapeutics Inc

CTOR

Citius Oncology Inc

HRTX

Heron Therapeutics Inc

Compare $CTOR vs $HRTX

Comparing Citius Oncology Inc and Heron Therapeutics Inc

CTORCitius Oncology Inc

HRTXHeron Therapeutics Inc

CTORCitius Oncology Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.10x

Rev growth (TTM)

—

YTD performance

-22.2%

52W performance

-54.4%

FCF yield

-24.8%

HRTXHeron Therapeutics Inc

Market cap

$77M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

1.0%

YTD performance

-67.8%

52W performance

-69.9%

FCF yield

-15.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CTOR

HRTX

Detailed metrics comparison

CTOR

Citius Oncology Inc

HRTX

Heron Therapeutics Inc

Market Cap

CTOR$78M

HRTX$77M

Enterprise Value

CTOR$72M

HRTX$199M

Price

CTOR$0.84

HRTX$0.41

P/E Ratio

CTORN/A

HRTXN/A

P/S Ratio

CTOR10.99x

HRTX0.51x

EV/Sales

CTOR10.10x

HRTX1.31x

EV/EBITDA

CTOR0.00x

HRTX79.76x

P/B Ratio

CTOR2.19x

HRTX9.55x

P/FCF Ratio

CTORN/A

HRTXN/A

EV/FCF

CTOR-3.70x

HRTX-16.38x

PEG Ratio

CTORN/A

HRTXN/A

Forward P/E (NTM)

CTORN/A

HRTXN/A

Forward P/S (NTM)

CTOR1.10x

HRTXN/A

Revenue (TTM)

CTOR$7M

HRTX$151M

Revenue Growth (YoY)

CTORN/A

HRTX1.0%

Forward Rev Growth

CTOR65.4%

HRTX-1.6%

Gross Margin (TTM)

CTOR77.3%

HRTX70.1%

Operating Margin (TTM)

CTOR0.0%

HRTX0.0%

EBITDA Margin (TTM)

CTOR-542.8%

HRTX-5.8%

Net Margin (TTM)

CTOR-648.3%

HRTX-22.5%

FCF Margin (TTM)

CTOR-272.9%

HRTX-8.0%

Net Income (TTM)

CTOR$-46M

HRTX$-34M

FCF (TTM)

CTOR$-19M

HRTX$-12M

EPS (TTM)

CTOR-$0.43

HRTX-$0.18

ROE (TTM)

CTOR-10298.0%

HRTX-30090.0%

ROA (TTM)

CTOR-4349.0%

HRTX-1357.0%

ROIC (TTM)

CTOR-9188.0%

HRTX-2233.0%

Cash

CTOR$17M

HRTX$21M

Debt

CTOR$10M

HRTX$143M

Net Cash/Debt

CTOR$6M

HRTX$-122M

Current Ratio (TTM)

CTOR0.73x

HRTX2.49x

Quick Ratio (TTM)

CTOR0.29x

HRTX1.44x

Debt/Equity (TTM)

CTOR0.25x

HRTX20.65x

Debt/Assets (TTM)

CTOR0.0%

HRTX0.0%

Interest Coverage (TTM)

CTORN/A

HRTXN/A

Net Debt/EBITDA (TTM)

CTOR0.00x

HRTX0.00x

Beta

CTOR3.34

HRTX1.65

52W Performance

CTOR-54.4%

HRTX-69.9%

YTD Performance

CTOR-22.2%

HRTX-67.8%

% from 52W High

CTOR-62.7%

HRTX-74.3%

% from 52W Low

CTOR71.0%

HRTX55.6%

Asset Turnover (TTM)

CTOR0.00x

HRTX0.60x

FCF Yield (TTM)

CTOR-24.8%

HRTX-15.8%

Earnings Yield (TTM)

CTOR-59.0%

HRTX-44.3%

Dividend Yield (TTM)

CTORN/A

HRTXN/A

Rule of 40

CTOR-272.9

HRTX-7.0

EV/GP/RG

CTOR0.01

HRTXN/A

Ticker research

View CTOR research View HRTX research

Metric	CTOR Citius Oncology Inc	HRTX Heron Therapeutics Inc
Market & Valuation
Market Cap	$78M	$77M
Enterprise Value	$72M	$199M
Price	$0.84	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	10.99x	0.51x
EV/Sales	10.10x	1.31x
EV/EBITDA	0.00x	79.76x
P/B Ratio	2.19x	9.55x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.70x	-16.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.10x	N/A
Revenue & Growth
Revenue (TTM)	$7M	$151M
Revenue Growth (YoY)	N/A	1.0%
Forward Rev Growth	65.4%	-1.6%
Profitability
Gross Margin (TTM)	77.3%	70.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-542.8%	-5.8%
Net Margin (TTM)	-648.3%	-22.5%
FCF Margin (TTM)	-272.9%	-8.0%
Net Income (TTM)	$-46M	$-34M
FCF (TTM)	$-19M	$-12M
EPS (TTM)	-$0.43	-$0.18
ROE (TTM)	-10298.0%	-30090.0%
ROA (TTM)	-4349.0%	-1357.0%
ROIC (TTM)	-9188.0%	-2233.0%
Financial Health
Cash	$17M	$21M
Debt	$10M	$143M
Net Cash/Debt	$6M	$-122M
Current Ratio (TTM)	0.73x	2.49x
Quick Ratio (TTM)	0.29x	1.44x
Debt/Equity (TTM)	0.25x	20.65x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.34	1.65
52W Performance	-54.4%	-69.9%
YTD Performance	-22.2%	-67.8%
% from 52W High	-62.7%	-74.3%
% from 52W Low	71.0%	55.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.60x
FCF Yield (TTM)	-24.8%	-15.8%
Earnings Yield (TTM)	-59.0%	-44.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-272.9	-7.0
EV/GP/RG	0.01	N/A
Ticker research	View CTOR research	View HRTX research

Valuation

P/S Ratio

HRTX

0.51x

CTOR

10.99x

EV/FCF

HRTX

-16.38x

CTOR

-3.70x

Growth & revenue

Revenue Growth TTM

HRTX

1.0%

Forward Revenue Growth

CTOR

65.4%

HRTX

-1.6%

Profitability & performance

Gross Margin

CTOR

77.3%

HRTX

70.1%

ROE

CTOR

-10298.0%

HRTX

-30090.0%

FCF Yield %

HRTX

-15.8%

CTOR

-24.8%

52-Week Performance

CTOR

-54.4%

HRTX

-69.9%

Detailed metrics comparison

CTOR

Citius Oncology Inc

HRTX

Heron Therapeutics Inc

Market Cap

CTOR$78M

HRTX$77M

Enterprise Value

CTOR$72M

HRTX$199M

Price

CTOR$0.84

HRTX$0.41

P/E Ratio

CTORN/A

HRTXN/A

P/S Ratio

CTOR10.99x

HRTX0.51x

EV/Sales

CTOR10.10x

HRTX1.31x

EV/EBITDA

CTOR0.00x

HRTX79.76x

P/B Ratio

CTOR2.19x

HRTX9.55x

P/FCF Ratio

CTORN/A

HRTXN/A

EV/FCF

CTOR-3.70x

HRTX-16.38x

PEG Ratio

CTORN/A

HRTXN/A

Forward P/E (NTM)

CTORN/A

HRTXN/A

Forward P/S (NTM)

CTOR1.10x

HRTXN/A

Revenue (TTM)

CTOR$7M

HRTX$151M

Revenue Growth (YoY)

CTORN/A

HRTX1.0%

Forward Rev Growth

CTOR65.4%

HRTX-1.6%

Gross Margin (TTM)

CTOR77.3%

HRTX70.1%

Operating Margin (TTM)

CTOR0.0%

HRTX0.0%

EBITDA Margin (TTM)

CTOR-542.8%

HRTX-5.8%

Net Margin (TTM)

CTOR-648.3%

HRTX-22.5%

FCF Margin (TTM)

CTOR-272.9%

HRTX-8.0%

Net Income (TTM)

CTOR$-46M

HRTX$-34M

FCF (TTM)

CTOR$-19M

HRTX$-12M

EPS (TTM)

CTOR-$0.43

HRTX-$0.18

ROE (TTM)

CTOR-10298.0%

HRTX-30090.0%

ROA (TTM)

CTOR-4349.0%

HRTX-1357.0%

ROIC (TTM)

CTOR-9188.0%

HRTX-2233.0%

Cash

CTOR$17M

HRTX$21M

Debt

CTOR$10M

HRTX$143M

Net Cash/Debt

CTOR$6M

HRTX$-122M

Current Ratio (TTM)

CTOR0.73x

HRTX2.49x

Quick Ratio (TTM)

CTOR0.29x

HRTX1.44x

Debt/Equity (TTM)

CTOR0.25x

HRTX20.65x

Debt/Assets (TTM)

CTOR0.0%

HRTX0.0%

Interest Coverage (TTM)

CTORN/A

HRTXN/A

Net Debt/EBITDA (TTM)

CTOR0.00x

HRTX0.00x

Beta

CTOR3.34

HRTX1.65

52W Performance

CTOR-54.4%

HRTX-69.9%

YTD Performance

CTOR-22.2%

HRTX-67.8%

% from 52W High

CTOR-62.7%

HRTX-74.3%

% from 52W Low

CTOR71.0%

HRTX55.6%

Asset Turnover (TTM)

CTOR0.00x

HRTX0.60x

FCF Yield (TTM)

CTOR-24.8%

HRTX-15.8%

Earnings Yield (TTM)

CTOR-59.0%

HRTX-44.3%

Dividend Yield (TTM)

CTORN/A

HRTXN/A

Rule of 40

CTOR-272.9

HRTX-7.0

EV/GP/RG

CTOR0.01

HRTXN/A

Ticker research

View CTOR research View HRTX research

Metric	CTOR Citius Oncology Inc	HRTX Heron Therapeutics Inc
Market & Valuation
Market Cap	$78M	$77M
Enterprise Value	$72M	$199M
Price	$0.84	$0.41
P/E Ratio	N/A	N/A
P/S Ratio	10.99x	0.51x
EV/Sales	10.10x	1.31x
EV/EBITDA	0.00x	79.76x
P/B Ratio	2.19x	9.55x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.70x	-16.38x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.10x	N/A
Revenue & Growth
Revenue (TTM)	$7M	$151M
Revenue Growth (YoY)	N/A	1.0%
Forward Rev Growth	65.4%	-1.6%
Profitability
Gross Margin (TTM)	77.3%	70.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-542.8%	-5.8%
Net Margin (TTM)	-648.3%	-22.5%
FCF Margin (TTM)	-272.9%	-8.0%
Net Income (TTM)	$-46M	$-34M
FCF (TTM)	$-19M	$-12M
EPS (TTM)	-$0.43	-$0.18
ROE (TTM)	-10298.0%	-30090.0%
ROA (TTM)	-4349.0%	-1357.0%
ROIC (TTM)	-9188.0%	-2233.0%
Financial Health
Cash	$17M	$21M
Debt	$10M	$143M
Net Cash/Debt	$6M	$-122M
Current Ratio (TTM)	0.73x	2.49x
Quick Ratio (TTM)	0.29x	1.44x
Debt/Equity (TTM)	0.25x	20.65x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.34	1.65
52W Performance	-54.4%	-69.9%
YTD Performance	-22.2%	-67.8%
% from 52W High	-62.7%	-74.3%
% from 52W Low	71.0%	55.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.60x
FCF Yield (TTM)	-24.8%	-15.8%
Earnings Yield (TTM)	-59.0%	-44.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-272.9	-7.0
EV/GP/RG	0.01	N/A
Ticker research	View CTOR research	View HRTX research